EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody–Drug Conjugates for the Treatment of Multiple Myeloma

Lorenzo Cani, Richa Parikh, Nisha S Joseph, Vikas A Gupta, Craig C Hofmeister, Jonathan L Kaufman, Ajay K Nooka, Sagar Lonial, Roberto Mina

Clinical Lymphoma Myeloma and Leukemia · 2026

DOI: 10.1016/j.clml.2026.03.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Lorenzo Cani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health S…. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Immunoconjugates, Immunotherapy, Adoptive. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Modern immunotherapies are reshaping the treatment landscape of multiple myeloma (MM), offering the possibility of deeper responses and prolonged survival. Over the past 5 years, chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies (BsAb), and antibody-drug conjugates have been developed and approved, first in the relapsed/refractory MM setting and progressively in earlier lines of therapy, underscoring a shift toward their use across the entire disease course, including at diagnosis. Concurrently, novel therapeutic constructs, such as trispecific antibodies, dual-target CAR T-cells, and combinations of different T-cell-redirecting therapies or their integration with standard agents, are currently under investigation across the entire treatment landscape. Despite their remarkable efficacy, these therapies are associated with distinct and clinically relevant toxicities that require careful understanding and management. These include well-recognized adverse events associated with CAR T-cell therapies and BsAb, such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, as well as an increased risk of infections, additional neurologic complications, and the ocular toxicity observed with belantamab mafodotin. In this review, we discuss the efficacy and safety profiles of CAR T-cell therapies, BsAb, and belantamab mafodotin within the current MM treatment landscape, highlighting evidence from both clinical trials and real-world studies, and providing an overview of available data on therapeutic sequencing strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, BispecificImmunoconjugatesImmunotherapy, AdoptiveAntibodies, Monoclonal, HumanizedNeoplasm Recurrence, LocalAntineoplastic Agents, ImmunologicalReceptors, Chimeric AntigenHumansT-LymphocytesCytokine Release SyndromeCombined Modality TherapyNeurotoxicity SyndromesClinical Trials as TopicProgression-Free SurvivalDrug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsB-Cell Maturation AntigenReceptors, G-Protein-Coupled

Stichwörter der Autor:innen

BCMABelantamab mafodotinGPRC5DImmunotherapiesSequencing

Substanzen

Antibodies, BispecificImmunoconjugatesAntineoplastic Agents, ImmunologicalReceptors, Chimeric Antigenbelantamab mafodotinAntibodies, Monoclonal, HumanizedB-Cell Maturation AntigenGPRC5D protein, humanReceptors, G-Protein-Coupled

Autor:innen und Institutionen

  • Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, Turin, Italy. Electronic address: lorenzo.cani1994@gmail.com.
  • Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.

Zitieren

APA

Cani, L., Parikh, R., Joseph, N. S., Gupta, V. A., Hofmeister, C. C., Kaufman, J. L., Nooka, A. K., Lonial, S., & Mina, R. (2026). The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody–Drug Conjugates for the Treatment of Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.03.003

Vancouver

Cani L, Parikh R, Joseph NS, Gupta VA, Hofmeister CC, Kaufman JL, et al. The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody–Drug Conjugates for the Treatment of Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.03.003

BibTeX
@article{Cani2026,
  author = {Cani, Lorenzo and Parikh, Richa and Joseph, Nisha S and Gupta, Vikas A and Hofmeister, Craig C and Kaufman, Jonathan L and Nooka, Ajay K and Lonial, Sagar and Mina, Roberto},
  title = {The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody–Drug Conjugates for the Treatment of Multiple Myeloma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2026.03.003}
}
Kostenlos starten →